FOR IMMEDIATE RELEASE
Middleton, WI, June 7, 2005 – Bone Care International, Inc. (Nasdaq: BCII) announced today that the U.S. Patent and Trademark Office has issued to it U.S. Patent Number 6,903,083 entitled “Stabilized hydroxyvitamin D.” The patent claims a stabilized 1α-hydroxyvitamin D2 and pharmaceutical products or compositions that include such an active component. The stabilized hydroxyvitamin D2 products covered under this patent are characterized by a purity profile defined by levels of impurities and residual solvents. Hectorol®, Bone Care’s novel vitamin D hormone therapy that treats secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease, is covered by this new composition of matter patent that will expire in 2021.
Mr. Paul Berns, President and Chief Executive Officer, Bone Care International stated, “This new patent on stabilized hydroxyvitamin D2 products expands the Hectorol®-related patent portfolio and extends the protected time horizon.”
Bone Care International (www.bonecare.com) is a specialty pharmaceutical company engaged in the discovery, development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Our current commercial and therapeutic focus is in nephrology, utilizing Hectorol®, a novel vitamin D hormone therapy, to treat secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition to chronic kidney disease, the Company is developing vitamin D hormone therapies to treat hyperproliferative disorders such as cancer and psoriasis.
Contact
Bone Care International, Inc.
Brian J. Hayden
Chief Financial officer
608-662-7800
This press release contains forward-looking statements. Statements relating to future sales, costs of sales, other expenses, profitability, financial resources, or products and production schedules, or statements that predict or indicate future events and trends and which do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management’s beliefs as well as assumptions made by and information currently available to management. Accordingly, the Company’s actual results may differ materially from those expressed or implied in such forward-looking statements due to known and unknown risks and uncertainties that exist in the Company’s operations and business environment, including, among other factors, the ability of the Company and each of its suppliers of doxercalciferol, Hectorol® Injection and Hectorol® Capsules to meet the Company’s anticipated production schedules, technical risks associated with the development of new products, regulatory policies in the United States and other countries, risks associated with our ability to avoid or minimize delays in/or interruption of the manufacture and supply of our products, including the approvals of regulatory authorities in connection therewith, reimbursement policies of public and private health care payors, introduction and acceptance of new drug therapies, competition from existing products and from new products or technologies, the failure by the Company to produce anticipated cost savings or improve productivity, the timing and magnitude of capital expenditures and acquisitions, currency exchange risks, economic and market conditions in the United States, Europe and the rest of the world, and other risks associated with the Company’s operations. The Company disclaims any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future events or developments.
